Alterity Therapeutics Ltd ADR (ATHE)

$3.43 +0.10 (3.12%)
Market Cap 29.49M
Revenue (ttm) 0.00
Net Income (ttm) -7.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,500
Avg Vol 13,266
Day's Range N/A - N/A
Shares Out 8.87M
Stochastic %K 46%
Beta 0.11
Analysts Strong Sell
Price Target $11.00

Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9349 4906
Fax: 61 3 9349 4906
Address:
350 Collins Street, Suite 4 Level 14, Melbourne, Australia
tommy_john
tommy_john Feb. 26 at 12:34 AM
$ATHE ready for the next wave!!
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 20 at 12:27 PM
$ATHE Current Stock Price: $3.37
0 · Reply
motherlandreturns
motherlandreturns Feb. 18 at 5:12 PM
$ATHE When is the next catalyst for this stock?
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 14 at 12:41 AM
$ATHE RSI: 46.71, MACD: 0.0437 Vol: 0.18, MA20: 3.36, MA50: 3.29 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DriftRunner
DriftRunner Feb. 10 at 2:31 PM
$ATHE is a biotech (Alterity Therapeutics) focused on neurodegenerative diseases; high-risk CNS development.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 12:02 PM
$ATHE Current Stock Price: $3.52
1 · Reply
CoachKenny
CoachKenny Feb. 7 at 10:46 PM
$ATHE 7000 shares and counting! Let’s save MSA patients and buy a lambo!
1 · Reply
GA09
GA09 Feb. 6 at 10:08 PM
$ATHE Closed above 20 & 50 DMA and golden cross between 20 & 50 DMA. Chart is constructive. Next resistance $4 (200 DMA). Needs some excellent news to break above 200 DMA.
0 · Reply
stckmuncher
stckmuncher Feb. 6 at 2:54 PM
$ATHE LFG!!!!!!!!
0 · Reply
stckmuncher
stckmuncher Feb. 6 at 2:53 PM
$ATHE BUY BUY BUY!!!!!!
0 · Reply
Latest News on ATHE
Alterity Therapeutics (ATHE) Advances Phase 3 Program with Strong Financials

2026-01-30T12:50:41.000Z - 27 days ago

Alterity Therapeutics (ATHE) Advances Phase 3 Program with Strong Financials

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

Fri, 30 Jan 2026 07:25:00 -0500 - 27 days ago

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

Alterity Therapeutics (ATHE) Advances towards Phase 3 Trials with Promising MSA Treatment

2026-01-21T12:51:15.000Z - 5 weeks ago

Alterity Therapeutics (ATHE) Advances towards Phase 3 Trials with Promising MSA Treatment

Alterity Therapeutics (ATHE) Pioneers Unique Approach to Neurodegeneration

2025-11-20T19:30:12.000Z - 3 months ago

Alterity Therapeutics (ATHE) Pioneers Unique Approach to Neurodegeneration

Alterity Therapeutics (ATHE) Focuses on Parkinson's Disease Research

2025-11-20T19:27:47.000Z - 3 months ago

Alterity Therapeutics (ATHE) Focuses on Parkinson's Disease Research

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Wed, 12 Nov 2025 07:25:00 -0500 - 3 months ago

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Fri, 31 Oct 2025 07:25:00 -0400 - 4 months ago

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Alterity Therapeutics (ATHE) Unveils Promising Phase 2 Results for ATH434 in MSA

2025-10-09T12:55:19.000Z - 5 months ago

Alterity Therapeutics (ATHE) Unveils Promising Phase 2 Results for ATH434 in MSA

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Thu, 09 Oct 2025 07:25:00 -0400 - 5 months ago

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Thu, 02 Oct 2025 07:35:00 -0400 - 5 months ago

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics (ATHE) Reports Promising Phase 2 Trial Results for ATH434

2025-09-15T12:53:11.000Z - 5 months ago

Alterity Therapeutics (ATHE) Reports Promising Phase 2 Trial Results for ATH434

Alterity Therapeutics (ATHE) Secures A$20M in New Funding

2025-09-08T13:28:02.000Z - 6 months ago

Alterity Therapeutics (ATHE) Secures A$20M in New Funding

Alterity Therapeutics raises A$20 million in strategic placement

2025-09-08T12:06:47.000Z - 6 months ago

Alterity Therapeutics raises A$20 million in strategic placement

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Mon, 08 Sep 2025 07:35:00 -0400 - 6 months ago

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Alterity Therapeutics to Present at the Biotech Showcase

Tue, 02 Sep 2025 07:25:00 -0400 - 6 months ago

Alterity Therapeutics to Present at the Biotech Showcase

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Wed, 30 Jul 2025 07:25:00 -0400 - 7 months ago

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Mon, 28 Jul 2025 07:25:00 -0400 - 7 months ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Thu, 24 Jul 2025 07:25:00 -0400 - 7 months ago

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

Mon, 23 Jun 2025 07:25:00 -0400 - 8 months ago

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

Alterity Therapeutics Prominently Featured at the International MSA Congress

Mon, 12 May 2025 07:35:00 -0400 - 10 months ago

Alterity Therapeutics Prominently Featured at the International MSA Congress

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

Wed, 07 May 2025 08:16:00 -0400 - 10 months ago

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Mon, 05 May 2025 07:35:00 -0400 - 10 months ago

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Wed, 30 Apr 2025 07:35:00 -0400 - 10 months ago

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Mon, 28 Apr 2025 07:35:00 -0400 - 10 months ago

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Thu, 10 Apr 2025 07:35:00 -0400 - 11 months ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Thu, 27 Mar 2025 07:25:00 -0400 - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Alterity Therapeutics raises A$40 million

2025-02-10T13:54:31.000Z - 1 year ago

Alterity Therapeutics raises A$40 million

Alterity Therapeutics Raises A$40.0 million in Placement

Mon, 10 Feb 2025 07:25:00 -0500 - 1 year ago

Alterity Therapeutics Raises A$40.0 million in Placement

Biotech company Alterity Therapeutics seeking to raise $40m

2025-02-05T22:25:26.000Z - 1 year ago

Biotech company Alterity Therapeutics seeking to raise $40m

What's Going On With Alterity Therapeutics Shares Thursday?

2025-01-30T15:39:39.000Z - 1 year ago

What's Going On With Alterity Therapeutics Shares Thursday?

Alterity surges after mid-stage trial data for lead asset

2025-01-30T13:32:39.000Z - 1 year ago

Alterity surges after mid-stage trial data for lead asset

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Thu, 30 Jan 2025 07:35:00 -0500 - 1 year ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Fri, 24 Jan 2025 07:35:00 -0500 - 1 year ago

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Thu, 09 Jan 2025 07:25:00 -0500 - 1 year ago

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Wed, 04 Dec 2024 07:35:00 -0500 - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Tue, 19 Nov 2024 07:25:00 -0500 - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Tue, 12 Nov 2024 07:35:00 -0500 - 1 year ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Wed, 06 Nov 2024 07:35:00 -0500 - 1 year ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Thu, 31 Oct 2024 07:35:00 -0400 - 1 year ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Mon, 14 Oct 2024 07:35:00 -0400 - 1 year ago

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Fri, 11 Oct 2024 07:35:00 -0400 - 1 year ago

Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Wed, 02 Oct 2024 07:35:00 -0400 - 1 year ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Alterity Therapeutics appoints Abby Macnish Niven as CFO

2024-09-30T12:00:38.000Z - 1 year ago

Alterity Therapeutics appoints Abby Macnish Niven as CFO

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Mon, 30 Sep 2024 07:35:00 -0400 - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Mon, 23 Sep 2024 07:35:00 -0400 - 1 year ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Wed, 31 Jul 2024 07:35:00 -0400 - 1 year ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

Alterity Therapeutics to Present at MST Financial Webinar

Wed, 24 Jul 2024 07:35:00 -0400 - 1 year ago

Alterity Therapeutics to Present at MST Financial Webinar

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Wed, 17 Jul 2024 07:35:00 -0400 - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Wed, 17 Jul 2024 07:25:00 -0400 - 1 year ago

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

Wed, 12 Jun 2024 19:22:00 -0400 - 1 year ago

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

May 29, 2024, 7:21 PM EDT - 1 year ago

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

ATHE

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

May 8, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

ATHE

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

Apr 30, 2024, 7:25 AM EDT - 1 year ago

Appendix 4C – Q3 FY24 Quarterly Cash Flow Report

ATHE

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

Apr 29, 2024, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

ATHE

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 17, 2024, 7:25 AM EDT - 2 years ago

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

ATHE

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

Apr 10, 2024, 7:25 AM EDT - 2 years ago

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

ATHE

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

Mar 26, 2024, 10:25 AM EDT - 2 years ago

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

ATHE

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

Feb 20, 2024, 10:25 AM EST - 2 years ago

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

ATHE

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Feb 6, 2024, 7:25 AM EST - 2 years ago

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

ATHE

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Jan 29, 2024, 7:24 AM EST - 2 years ago

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

ATHE

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

Dec 21, 2023, 12:30 AM EST - 2 years ago

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

ATHE

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

Dec 4, 2023, 4:35 PM EST - 2 years ago

Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

ATHE

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

Dec 4, 2023, 7:25 AM EST - 2 years ago

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

ATHE

tommy_john
tommy_john Feb. 26 at 12:34 AM
$ATHE ready for the next wave!!
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 20 at 12:27 PM
$ATHE Current Stock Price: $3.37
0 · Reply
motherlandreturns
motherlandreturns Feb. 18 at 5:12 PM
$ATHE When is the next catalyst for this stock?
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 14 at 12:41 AM
$ATHE RSI: 46.71, MACD: 0.0437 Vol: 0.18, MA20: 3.36, MA50: 3.29 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DriftRunner
DriftRunner Feb. 10 at 2:31 PM
$ATHE is a biotech (Alterity Therapeutics) focused on neurodegenerative diseases; high-risk CNS development.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 12:02 PM
$ATHE Current Stock Price: $3.52
1 · Reply
CoachKenny
CoachKenny Feb. 7 at 10:46 PM
$ATHE 7000 shares and counting! Let’s save MSA patients and buy a lambo!
1 · Reply
GA09
GA09 Feb. 6 at 10:08 PM
$ATHE Closed above 20 & 50 DMA and golden cross between 20 & 50 DMA. Chart is constructive. Next resistance $4 (200 DMA). Needs some excellent news to break above 200 DMA.
0 · Reply
stckmuncher
stckmuncher Feb. 6 at 2:54 PM
$ATHE LFG!!!!!!!!
0 · Reply
stckmuncher
stckmuncher Feb. 6 at 2:53 PM
$ATHE BUY BUY BUY!!!!!!
0 · Reply
Nimmer
Nimmer Feb. 6 at 12:08 PM
$ATHE Highest volume i Australia yesterday in 10 month, 10 times the volume the day before.
2 · Reply
RocketMan88
RocketMan88 Feb. 5 at 8:01 PM
$ATHE today’s volume has nearly doubled the daily average with an hour left of trading. That lifted volume showed some solid gains. Couple more days like this I can rename my plane the ATHE express.
1 · Reply
RemitTekram
RemitTekram Feb. 5 at 1:46 PM
$ATHE
0 · Reply
RocketMan88
RocketMan88 Feb. 4 at 10:50 PM
$ATHE can’t wait to wake up a multi-millionare tomorrow
2 · Reply
stckmuncher
stckmuncher Feb. 4 at 4:19 PM
$ATHE Nice movement on relatively low volume!!! ✅
0 · Reply
stckmuncher
stckmuncher Feb. 3 at 4:34 PM
$ATHE Big money coming!
1 · Reply
RocketMan88
RocketMan88 Feb. 3 at 3:48 PM
$ATHE $5 floor here we come!
0 · Reply
GA09
GA09 Jan. 30 at 1:44 AM
$ATHE This is extremely positive along with the rest of the update. They are ready for the EO2 meeting with the FDA and are already having partnering discussions with a number of pharmaceutical companies. From my experience, their chance of being acquired increases once they are aligned on Phase 3 trial with the FDA.
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Jan. 30 at 1:16 AM
$ATHE looking strong lads https://alteritytx.com/announcements/7333308
1 · Reply
anastasia_beaverhausen1
anastasia_beaverhausen1 Jan. 29 at 11:49 PM
$ATHE new PR https://alteritytx.com/announcements/7333308
0 · Reply
stckmuncher
stckmuncher Jan. 29 at 2:32 AM
$ATHE WE OUT HERE!
0 · Reply
stckmuncher
stckmuncher Jan. 29 at 2:30 AM
$ATHE My buddy has 10k shares!
0 · Reply